Milea Timbergen

173 Table 5. Published results regarding variables that are potentially associated with time to disease stabilisation, risk of progression or change in treatment strategy. Significant outcomes (p-value <0.05) are in bold. Ref Outcome p-value Statistically significant identified risk factor Barbier, 2010 27 Time difference in evolution to stabilisation  Primary vs. recurrent disease p = 0.0417 Longer evolution time before stabilization in recurrent tumours Kim, 2020 37  Age  Tumour status  Tumour site (axial vs. extremity) p = 0.022 p = 0.041 p = 0.148 Age, < 40 years and recurrent tumours are predictive factors of longer time to disease stabilization Bonvalot, 2013 10 Change in treatment strategy  Pregnancy before the development of DTF  Age  Tumour size   3.5-5.0 cm (HR 3.7, 95% CI 1.0% to 14%)   5-7 cm (HR 4.0, 95% CI 2.4% to 2.8%)   7-15.6 cm (HR 8.2, 95% CI 2.4% to 28%) p = 0.27 p = 0.27 p = 0.004 Larger tumour size (>3.5) Cassidy, 2018 31 Change in treatment strategy  Age  Sex  Documentation of symptoms at  presentation PFS a  Age (HR 0.99)  Tumour size (HR 1,027)  Tumour site extremities/all other sites  vs. abdominal wall  Tumour site paraspinal/flank  vs abdominal wall p = 0.22 p = 0.07 p = 0.35 p = 0.31 p= 0.13 p = 0.54/ p = 0.38 p = 0.01 Colombo, 2015 9 Change in treatment strategy  Sex  Tumour site  Size p = 0.565 p = 0.926 p = 0.397 Turner, 2019 38 Progression  Tumour site abdominal wall vs. other sites p = 0.53 Van Houdt, 2019 36 Change in treatment strategy  Tumour size >7 cm (HR 2.04, 95%  CI 1.29% to 3.21%)  Reporting pain  PR vs. SD, PD  Age  Tumour site  Sex p < 0.01 p < 0.001 p < 0.001 p = 0.13 p = 0.36 p = 0.84 Larger tumour size (>7 cm), reporting pain, and stable disease or progressive disease are associated with a higher risk of initiation of an active form of treatment CI, confidence interval; HR, hazard ratio; PD, progressive disease; PFS. Progression-free survival; PR, partial response; SD, stable disease a only available for n = 37 patients with evaluable magnetic resonance imaging 6